{"id":23568,"date":"2026-05-02T15:21:36","date_gmt":"2026-05-02T15:21:36","guid":{"rendered":"https:\/\/www.europesays.com\/news\/23568\/"},"modified":"2026-05-02T15:21:36","modified_gmt":"2026-05-02T15:21:36","slug":"psychedelics-should-be-more-available-to-people-from-minority-groups","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/news\/23568\/","title":{"rendered":"Psychedelics should be more available to people from minority groups"},"content":{"rendered":"

Flanked by one of\u00a0psychedelics\u2019 biggest celebrity cheerleaders, Joe Rogan, and a troupe of MAHA loyalists, President Trump recently signed an executive order<\/a> aimed at accelerating\u00a0psychedelic access for clinical research and treatment.<\/p>\n

Use of naturally occurring and synthetic hallucinogens traces back to the Neanderthals<\/a>. Yet these substances have long been a pariah in mainstream medicine, written off as \u201cclub drugs\u201d with little to no clinical value<\/a> (or worse, downright negative effects<\/a>).<\/p>\n

But they no longer sit on the fringes of medicine. In August, for instance, pharmaceutical giant AbbVie inked a billion-dollar deal, the first of its kind, to acquire Bretisilocin<\/a>, a psychedelic compound used to treat major depressive disorder. Now Trump is directing federal agencies to streamline regulatory pathways, expand clinical trials, and explore mechanisms for broader therapeutic use. With the federal government formally throwing its hat in the ring, this is likely just the start of a much broader trend of Big Pharma investing heavily in the drugs.<\/p>\n

As researchers who focus on mental illness and addiction, we see psychedelics\u2019 potential as a form of treatment as virtually unmatched. But their promise faces both scientific uncertainty<\/a> and thorny political questions \u2014 especially when it comes to their benefits outside of white populations.<\/p>\n

Today, psychedelics\u2019 applications are more expansive than ever, having evolved well beyond their role as a treatment for mental illness<\/a> to a clinical Swiss Army knife that appears to help conditions ranging from opioid addiction<\/a> and chronic pain<\/a> to eating disorders<\/a>. The global psychedelics market is expected to reach roughly $11.7 billion by 2029<\/a>.<\/p>\n

\t\t\t\"\"\t\t<\/p>\n

\t\t\t\t\"\"\/
\n\t\t\t\tSTAT Plus: FDA to speed up review of three psychedelics as mental health treatments<\/a><\/p>\n

Currently, the most clinically \u2014 and politically \u2014 promising psychedelic is ibogaine. Ibogaine has shown efficacy in addressing depression, trauma, and substance use disorders<\/a> and has gained praise from veterans with PTSD<\/a>. Evidence of ibogaine\u2019s increasing clout can be seen in its broad embrace outside of the white liberal enclaves typically at the forefront of drug legalization efforts, like Oregon and Washington state. For example, in June, Rick Perry, former Republican governor of Texas and secretary of energy during Trump\u2019s first term, published an op-ed<\/a> in The Washington Post calling for a legal embrace of ibogaine. (He\u2019s also discussed his personal experience with the hallucinogen<\/a>.) Former Republican House Speaker Newt Gingrich offered a similar co-sign on his podcast last summer<\/a>.<\/p>\n

In a YouGov poll<\/a>, 28% of Americans indicated they had tried at least one of seven different psychedelics. The number of adults who have ever used psilocybin (magic mushrooms), America\u2019s most popular psychedelic, increased from 25 million in 2019 to 31.3 million in 2023<\/a>.<\/p>\n

Retired boxer Mike Tyson, whose rage in and outside of the ring became the stuff of legend in the \u201990s, has frequently sung psychedelics\u2019 praises. \u201cEveryone thought I was crazy,\u201d the heavyweight boxer said in an interview with Reuters<\/a>, going on to mention his ignominious bout with Evander Holyfield in 1997. \u201cI bit this guy\u2019s ear off.\u201d Tyson\u2019s introduction to psilocybin proved life-altering. \u201cI did all this stuff, and once I got introduced to the shrooms \u2026 my whole life changed.\u201d<\/p>\n

Without a doubt, white people are psychedelics\u2019 biggest audience. According to one study<\/a>, 12% of non-Hispanic white Americans have used psilocybin at some point in their lives, compared with 3.4% of non-Hispanic racial and ethnic minorities (3.4%). Similar racial gaps have been observed for MDMA (ecstasy)<\/a>, LSD, and mescaline<\/a>. White people are even consuming psychedelics deeply associated with Indigenous culture<\/a>, like peyote and ayahuasca.<\/p>\n

It\u2019s racial minorities, though, who could gain the most from the use of psychedelics. The two of us been studying why they haven\u2019t so far.<\/p>\n

Black people experience higher levels of early-life post-traumatic stress<\/a> than white people and are more likely to suffer from chronic depression later in life<\/a>. Moreover, while suicide has been on the decline in white populations<\/a> in recent years, rates have steadily increased among Black people, and attempts remain highest among Indigenous Americans<\/a>.<\/p>\n

On the substance use end,\u00a0a study from our research team<\/a> found that Black, Latino, and Indigenous people generally have higher rates of opioid overdose deaths relative to white people. Psychedelics \u2014 medically dynamic and relatively easy to procure and process for clinical use \u2014 look heaven-sent in their potential to address persistent health disparities like these.<\/p>\n

Yet racial minorities haven\u2019t benefited from the psychedelic renaissance. In fact, studies from our team and others consistently show<\/a> that racial minority groups tend to experience substantially fewer clinical benefits from psychedelic use relative to non-Hispanic white people. One study published last June<\/a> found that psychedelic use for Black and Hispanic users didn\u2019t reduce their distress levels; however, among white psychedelic users, usage was associated with lower distress levels. Another study<\/a> found that non-Hispanic white participants who had used psilocybin had reduced odds of hypertension. However, no such associations were observed for Black, Hispanic, Asian, Indigenous, or multiracial study participants.<\/p>\n

There\u2019s a key reason for findings like these: the persistent exclusion of racial minorities from psychedelics research.<\/p>\n

Compared with white people, Black people and other racial minorities have historically participated far less in clinical trials<\/a> \u2014 the primary staging ground for exploring the efficacy and safety of drugs. Minorities\u2019 limited participation<\/a> is due primarily to researchers\u2019 lackluster outreach efforts and minorities\u2019 deeply rooted mistrust of research and the medical establishment.<\/p>\n

Compounding the problem, psychedelics are frequently best when taken in safe, comforting spaces<\/a> that encourage openness. People with chronically negative experiences, for example with racism<\/a>, may struggle to embrace the \u201ctrip\u201d and absorb the full range of fruits it can potentially offer.<\/p>\n

Researchers haven\u2019t yet figured out how to tailor psychedelic regimens to the unique social, somatic, and psychological profiles of racial minorities. The Trump administration\u2019s ongoing antagonism toward race-focused research<\/a> adds an obvious wrinkle to addressing this issue.<\/p>\n

Despite this, there\u2019s a clear appetite for psychedelics among racial minorities. A study showed that when Black and white people were educated on psychedelic-assisted therapy, Black people had more positive views on it<\/a>. And, unsurprisingly, this interest was related to unmet need: individuals with greater depression and PTSD symptoms, particularly Black participants,<\/a> expressed higher levels of interest in psychedelic-assisted therapy.<\/p>\n

Lastly, there\u2019s the issue of criminalization, which impacts not just access but patterns of societal stigma toward drugs<\/a>. In recent years, a number of American cities, including several with large Black populations \u2014 like Oakland, Calif.; Detroit; and Washington, D.C. \u2014 have crafted laws to eliminate criminal penalties for recreational usage and in some cases to make psychedelics more accessible. Whatever President Trump\u2019s endgame, most psychedelics will likely remain illegal at the federal level<\/a>, even as some companies operate in a legal gray area (for example retreats, ketamine clinics). These spaces exist alongside, not outside of, America\u2019s hugely ineffective<\/a> \u2014 and highly racialized \u2014 War on Drugs. And the War on Drugs indeed looms large in consideration of how race may impact the enforcement of future federal and state-level psychedelics policies. The real implications come into focus at the point of use.<\/p>\n

The majority of psychedelic use is without incident<\/a>, but there are exceptions. When they occur, they can be especially detrimental to the safety of racial minorities, whose usage is frequently framed as problematic<\/a> rather than spiritual or part of a soul-searching process. Black and Latino men, for example, are more likely than white men to be arrested for severe mental illness-related behavior<\/a>, such as psychosis, which has a modest connection to psychedelics<\/a>.<\/p>\n

Given how entrenched and complex our public health challenges are, we can\u2019t afford to not capture the lightning-in-a-bottle that psychedelics offer. Fortunately, psychedelics as a field is still in its infancy, and there\u2019s time to calibrate the science and racial sensitivity in a way that makes the drug safe, effective, and inclusive. We don\u2019t have to sacrifice one benefit to secure the others.<\/p>\n

Jerel Ezell, Ph.D., M.P.H., is a social epidemiologist and assistant professor at the University of Chicago Medical Center. He studies the social and racial aspects of health. Sugy Choi, Ph.D., M.P.H., is a health services researcher and assistant professor at New York University Grossman School of Medicine. She studies health policy and equitable access to care.<\/p>\n","protected":false},"excerpt":{"rendered":"Flanked by one of\u00a0psychedelics\u2019 biggest celebrity cheerleaders, Joe Rogan, and a troupe of MAHA loyalists, President Trump recently…\n","protected":false},"author":2,"featured_media":23569,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[4151,14440,8,928,9,147,14441,7],"class_list":{"0":"post-23568","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-top-stories","8":"tag-access","9":"tag-diversity-and-inclusion","10":"tag-headlines","11":"tag-mental-health","12":"tag-news","13":"tag-policy","14":"tag-psychedelics","15":"tag-top-stories"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@news\/116505666101004725","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/posts\/23568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/comments?post=23568"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/posts\/23568\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/media\/23569"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/media?parent=23568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/categories?post=23568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/tags?post=23568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}